Impact of multisite artery disease on clinical outcomes after percutaneous coronary intervention: an analysis from the e-Ultimaster registry
- PMID: 35876646
- PMCID: PMC10284265
- DOI: 10.1093/ehjqcco/qcac043
Impact of multisite artery disease on clinical outcomes after percutaneous coronary intervention: an analysis from the e-Ultimaster registry
Abstract
Background: Multisite artery disease is considered a 'malignant' type of atherosclerotic disease associated with an increased cardiovascular risk, but the impact of multisite artery disease on clinical outcomes after percutaneous coronary intervention (PCI) is unknown.
Methods: Patients enrolled in the large, prospective e-Ultimaster study were grouped into (1) those without known prior vascular disease, (2) those with known single-territory vascular disease, and (3) those with known two to three territories (i.e coronary, cerebrovascular, or peripheral) vascular disease (multisite artery disease). The primary outcome was coronary target lesion failure (TLF), defined as the composite of cardiac death, target vessel-related myocardial infarction, and clinically driven target lesion revascularization at 1-year. Inverse propensity score weighted (IPSW) analysis was performed to address differences in baseline patient and lesion characteristics.
Results: Of the 37 198 patients included in the study, 62.3% had no prior known vascular disease, 32.6% had single-territory vascular disease, and 5.1% had multisite artery disease. Patients with known vascular disease were older and were more likely to be men and to have more co-morbidities. After IPSW, the TLF rate incrementally increased with the number of diseased vascular beds (3.16%, 4.44%, and 6.42% for no, single, and multisite artery disease, respectively, P < 0.01 for all comparisons). This was also true for all-cause death (2.22%, 3.28%, and 5.29%, P < 0.01 for all comparisons) and cardiac mortality (1.26%, 1.91%, and 3.62%, P ≤ 0.01 for all comparisons).
Conclusions: Patients with previously known vascular disease experienced an increased risk of adverse cardiovascular events and mortality post-PCI. This risk is highest among patients with multisite artery disease.
Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02188355.
Keywords: Poly-vascular disease; clinical trial; human; percutaneous coronary intervention; vascular disease.
© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.
Conflict of interest statement
Authors’ contributions
Drafting of the manuscript: O.K., M.S., and A.R.
Critical revision of the manuscript for important intellectual content: C.v.B., P.A.L.T., A.I.-R., O.F., M.H., R.M.O., J.P., A.J.J.I., A.A., M.R., and M.A.M.
Data availability
Data are available upon reasonable request from the study sponsor.
Figures
References
-
- Darmon A, Elbez Y, Bhatt DL, Abtan J, Mas JL, Cacoub Pet al. . Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry. Ann Cardiol Angeiol (Paris) 2020;69:158–166. - PubMed
-
- Shi R, Babu S. Modern approaches and innovations in the diagnosis and treatment of peripheral vascular diseases. Front Biosci (Schol Ed) 2021;13:173–180. - PubMed
-
- Aboyans V, Ricco J-B, Bartelink M-LEL, Björck M, Brodmann M, Cohnert Tet al. . 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries endorsed by: the European Stroke Organization (ESO) the Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2018;39:763–816. - PubMed
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
